{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:35:22Z","timestamp":1787027722365,"version":"build-2736575974"},"reference-count":98,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Antibody\u2013drug conjugates (ADCs) are a rapidly evolving class of oncology therapeutics that enable precise delivery of potent cytotoxic agents to tumor cells while minimizing systemic toxicity. While HER2-targeted ADCs such as trastuzumab deruxtecan (T-DXd) in HER2-mutant, Datopotamab deruxtecan (Dato-Dxd) in EGFR-mutant, and telisotumumab vedotin (Teliso-V) in MET IHC 3+ expressing lung cancer have already established a clinical role in non-small cell lung cancer (NSCLC), multiple ADCs targeting alternative antigens, including additional TROP2 ADCs, HER3, MET, CEACAM5, B7-H3, Nectin-4, and others, are now in advanced clinical development. This review synthesizes the current evidence for non-HER2 ADCs in NSCLC, highlighting mechanisms of action, clinical efficacy, safety profiles, biomarker strategies, and emerging resistance mechanisms. Key safety concerns, including interstitial lung disease (ILD), ocular toxicity, and peripheral neuropathy, are emphasized alongside approaches for re-challenge following toxicity. We further discuss next-generation ADC platforms, including bispecific and conditionally activated constructs, as well as combination strategies with immunotherapy. Collectively, ADCs beyond HER2 are poised to reshape treatment paradigms in NSCLC, offering hope for patients with limited therapeutic options. This review identifies current gaps, highlights ongoing research priorities, and proposes practical considerations for integrating these therapies into clinical practice.<\/jats:p>","DOI":"10.3390\/biom16050677","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:06:21Z","timestamp":1777860381000},"page":"677","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody\u2013Drug Conjugates Beyond HER2 in Non-Small Cell Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future Directions"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1587-0370","authenticated-orcid":false,"given":"Ahmed","family":"Ismail","sequence":"first","affiliation":[{"name":"Department of Medicine, Eastern Virginia Medical School at Old Dominion University, Norfolk, VA 23507, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, O\u2019Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35487, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ohio Health, Columbus, OH 43228, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanis","family":"Boumber","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ohio Health, Delaware, OH 43015, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ismail, A., Desai, A., and Boumber, Y. (2025). HER2 alterations in non-small cell lung cancer (NSCLC): From biology and testing to advances in treatment modalities. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1624124"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","article-title":"Recent advances in non-small cell lung cancer targeted therapy; an update review","volume":"23","author":"Araghi","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-Drug Conjugates (ADCs): Current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-Drug Conjugate-Based Therapeutics: State of the Science","volume":"111","author":"Birrer","year":"2019","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gogia, P., Ashraf, H., Bhasin, S., and Xu, Y. (2023). Antibody\u2013Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence. Cancers, 15.","DOI":"10.3390\/cancers15153886"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"oyaf258","DOI":"10.1093\/oncolo\/oyaf258","article-title":"HER2 alterations across solid tumors: Implications for comprehensive testing","volume":"30","author":"Ismail","year":"2025","journal-title":"Oncologist"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer with Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study","volume":"43","author":"Sands","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5582\/ddt.2025.01058","article-title":"Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC)","volume":"19","author":"Zhao","year":"2025","journal-title":"Drug Discov. Ther."},{"key":"ref_13","unstructured":"(2026, January 10). Randomized, Open-Label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-Small-Cell Lung Cancer Patients with CEACAM5-Positive Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04154956."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-Drug Conjugates: A Comprehensive Review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody-drug conjugates in cancer therapy: Current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: Fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104979","DOI":"10.1016\/j.critrevonc.2025.104979","article-title":"Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity","volume":"216","author":"Wang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Tang, Z., Xie, Y., and Zeng, Y. (2025). Antibody-drug conjugate: A newly developed biological missile for tumor treatment. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1688057"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Cheng, Y., Yuan, X., Tian, Q., Huang, X., Chen, Y., Pu, Y., Long, H., Xu, M., Ji, Y., and Xie, J. (2022). Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.951589"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1158\/1078-0432.CCR-21-0765","article-title":"Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma","volume":"27","author":"Camidge","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab Vedotin Monotherapy in Patients with Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: A first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.annonc.2021.12.012","article-title":"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study","volume":"33","author":"Gazzah","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_25","first-page":"100844","article-title":"Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients with Nonsquamous NSCLC with High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5","volume":"6","author":"Gazzah","year":"2025","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"217681","DOI":"10.1016\/j.canlet.2025.217681","article-title":"Nectin-4 expression patterns and therapeutics in oncology","volume":"622","author":"Nikanjam","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"115603","DOI":"10.1016\/j.ejca.2025.115603","article-title":"Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1\/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study","volume":"227","author":"Muro","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_28","unstructured":"(2026, January 10). DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of Advanced Cancer. Available online: https:\/\/daiichisankyo.us\/press-releases\/-\/article\/ds-7300-continues-to-show-promising-durable-response-in-patients-with-several-types-of-advanced-cancer."},{"key":"ref_29","unstructured":"(2026, January 10). Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial. Available online: https:\/\/daiichisankyo.us\/press-releases\/-\/article\/ifinatamab-deruxtecan-continues-to-demonstrate-durable-responses-in-patients-with-advanced-small-cell-lung-cancer-in-early-trial."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Alanazi, A.S., Alanazi, A.A., Alanizi, A., Babalghaith, R., Alotaibi, R., Alnuhait, M., and Bakhribah, H. (2025). Trastuzumab Deruxtecan-Associated Interstitial Lung Disease: Real-World Insights from a Tertiary Care Center. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32100575"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zanchetta, C., De Marchi, L., Macerelli, M., Pelizzari, G., Costa, J., Aprile, G., and Cortiula, F. (2025). Antibody\u2013Drug Conjugates in Non-Small Cell Lung Cancer: State of the Art and Future Perspectives. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26010221"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40261-025-01447-6","article-title":"Risk of Ophthalmotoxicity Associated with Antibody-Drug Conjugates: A Systematic Review and Meta-analysis","volume":"45","author":"Feng","year":"2025","journal-title":"Clin. Drug Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"pkad069","DOI":"10.1093\/jncics\/pkad069","article-title":"Toxicity profiles of antibody-drug conjugates for anticancer treatment: A systematic review and meta-analysis","volume":"7","author":"Suzuki","year":"2023","journal-title":"JNCI Cancer Spectr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e70178","DOI":"10.1111\/1759-7714.70178","article-title":"Treatment-Related Adverse Events of Antibody-Drug Conjugate Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"16","author":"Li","year":"2025","journal-title":"Thorac. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_39","unstructured":"(2026, January 10). USDS Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients with Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial. Available online: https:\/\/daiichisankyo.us\/press-releases\/-\/article\/novel-computational-pathology-based-trop2-biomarker-for-datopotamab-deruxtecan-was-predictive-of-clinical-outcomes-in-patients-with-non-small-cell-lun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","article-title":"Therapy of Advanced Non-Small-Cell Lung Cancer with an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan","volume":"35","author":"Heist","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study","volume":"42","author":"Mountzios","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa2512071","article-title":"Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC","volume":"394","author":"Fang","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_43","unstructured":"(2026, January 10). Press Release: Sanofi Announces End of Program Evaluating Tusamitamab Ravtansine After a 2L NSCLC Phase 3 Trial Did Not Meet a Primary Endpoint. Available online: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2023\/2023-12-21-06-30-00-2799759."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2217\/fon-2022-1250","article-title":"HERTHENA-Lung01: A phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC","volume":"19","author":"Yu","year":"2023","journal-title":"Future Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","article-title":"Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib","volume":"36","author":"Horinouchi","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000522206","article-title":"Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors","volume":"89","author":"Dum","year":"2022","journal-title":"Pathobiology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1101\/gad.1692008","article-title":"A branched-chain fatty acid is involved in post-embryonic growth control in parallel to the insulin receptor pathway and its biosynthesis is feedback-regulated in C. elegans","volume":"22","author":"Kniazeva","year":"2008","journal-title":"Genes Dev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/1078-0432.CCR-24-1525","article-title":"The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors","volume":"31","author":"Tolaney","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-24-0428","article-title":"Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1\/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"144","DOI":"10.18632\/oncotarget.28559","article-title":"Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas","volume":"15","author":"Cardillo","year":"2024","journal-title":"Oncotarget"},{"key":"ref_51","unstructured":"(2026, January 10). An Open-Label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05186974."},{"key":"ref_52","unstructured":"(2026, January 10). An Open-Label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination with Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-Line Treatment in Participants with PD L1 TPS Greater Than or Equal to 50% Metastatic Non-Small Cell Lung Cancer (KEYNOTE D46\/EVOKE-03), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05609968."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"519","DOI":"10.4048\/jbc.2023.26.e38","article-title":"Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report","volume":"26","author":"Schutte","year":"2023","journal-title":"J. Breast Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.annonc.2025.07.015","article-title":"Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease\/pneumonitis","volume":"36","author":"Rugo","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40291-021-00568-w","article-title":"MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review","volume":"26","author":"Dong","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"101266","DOI":"10.1016\/j.drup.2025.101266","article-title":"Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer","volume":"82","author":"Du","year":"2025","journal-title":"Drug Resist. Updates"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.22.00739","article-title":"Phase Ib Study of Telisotuzumab Vedotin in Combination with Erlotinib in Patients with c-Met Protein\u2013Expressing Non\u2013Small-Cell Lung Cancer","volume":"41","author":"Camidge","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"oyaf331","DOI":"10.1093\/oncolo\/oyaf331","article-title":"Antibody drugs conjugates in non\u2013Small cell lung cancer: Current status and challenges","volume":"30","author":"Syal","year":"2025","journal-title":"Oncologist"},{"key":"ref_60","first-page":"100262","article-title":"A Phase 1b Study of Telisotuzumab Vedotin in Combination with Nivolumab in Patients with NSCLC","volume":"3","author":"Camidge","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_61","first-page":"355","article-title":"HER3 signaling and targeted therapy in cancer","volume":"12","author":"Mishra","year":"2018","journal-title":"Oncol. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7406","DOI":"10.1038\/s41598-019-43678-6","article-title":"EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients","volume":"9","author":"Scharpenseel","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1200\/JCO.23.00882","article-title":"Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients with Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I\/II Trial","volume":"41","author":"Krop","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1038\/s41591-025-03885-3","article-title":"Patritumab deruxtecan in HR+HER2\u2212 advanced breast cancer: A phase 2 trial","volume":"31","author":"Pistilli","year":"2025","journal-title":"Nat. Med."},{"key":"ref_65","unstructured":"(2026, January 10). A Phase 3, Randomized, Open-Label Study of Patritumab Deruxtecan Versus Platinum-Based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-Mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05338970."},{"key":"ref_66","unstructured":"(2026, January 10). Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENALung02 Phase 3 Trial. Available online: https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202409\/20240917_E.pdf?utm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"300060520959478","DOI":"10.1177\/0300060520959478","article-title":"CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration","volume":"48","author":"Zhang","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1158\/1078-0432.CCR-16-3107","article-title":"B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes","volume":"23","author":"Altan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2020.03.033","article-title":"Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer","volume":"133","author":"Yim","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Zhang, J., Zhou, Z., Chen, K., Kim, S., Cho, I.S., Varadkar, T., Baker, H., Cho, J.H., Zhou, L., and Liu, X. (2023). A CD276-Targeted Antibody-Drug Conjugate to Treat Non-Small Lung Cancer (NSCLC). Cells, 12.","DOI":"10.3390\/cells12192393"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cllc.2020.09.013","article-title":"Phase II Study of Telisotuzumab Vedotin in Patients with c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)","volume":"22","author":"Waqar","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"100764","DOI":"10.1016\/j.tranon.2020.100764","article-title":"Heterogeneous Drug Efficacy of an Antibody-Drug Conjugate Visualized Using Simultaneous Imaging of Its Delivery and Intracellular Damage in Living Tumor Tissues","volume":"13","author":"Gonda","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody\u2013drug conjugates: A review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Shan, K.S., Musleh Ud Din, S., Dalal, S., Gonzalez, T., Dalal, M., Ferraro, P., Hussein, A., and Vulfovich, M. (2025). Bispecific Antibodies in Solid Tumors: Advances and Challenges. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26125838"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pccm.2022.12.001","article-title":"HER3-targeted therapeutic antibodies and antibody-drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors","volume":"1","author":"Larsen","year":"2023","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Hafeez, U., Parakh, S., Gan, H.K., and Scott, A.M. (2020). Antibody-Drug Conjugates for Cancer Therapy. Molecules, 25.","DOI":"10.3390\/molecules25204764"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_79","first-page":"A1594","article-title":"1426 The anti-tumor activity of a novel anti-Her2\/anti-Trop2 bispecific VHH antibody-drug conjugate (ADC)","volume":"12","author":"Zhong","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00280-025-04863-9","article-title":"Recent advances in bispecific antibody-drug conjugates for breast cancer therapy","volume":"96","author":"Ji","year":"2026","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41392-021-00833-8","article-title":"From prodrug to pro-prodrug: Hypoxia-sensitive antibody\u2013drug conjugates","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: A key step in the development of antibody\u2013drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Alradwan, I.A., Alnefaie, M.K., Al Fayez, N., Aodah, A.H., Majrashi, M.A., Alturki, M., Fallatah, M.M., Almughem, F.A., Tawfik, E.A., and Alshehri, A.A. (2025). Strategic and Chemical Advances in Antibody-Drug Conjugates. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17091164"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/mabs.27022","article-title":"Site-specific antibody drug conjugates for cancer therapy","volume":"6","author":"Panowski","year":"2014","journal-title":"MAbs"},{"key":"ref_85","first-page":"262","article-title":"Reprogramming the tumor microenvironment: Synergistic mechanisms of antibody-drug conjugates and immune checkpoint inhibitors","volume":"8","author":"Yin","year":"2025","journal-title":"Antib. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"103509","DOI":"10.1016\/j.jtho.2025.10.016","article-title":"First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS","volume":"21","author":"Reck","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"ref_87","unstructured":"(2026, January 10). A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05555732."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Hsu, R., and Benjamin, D.J. (2023). A narrative review of antibody-drug conjugates in EGFR-mutated non-small cell lung cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1252652"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Chen, Q., Jia, G., Zhang, X., and Ma, W. (2023). Targeting HER3 to overcome EGFR TKI resistance in NSCLC. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1332057"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41698-025-00885-x","article-title":"Spatially precise chemo-radio-immunotherapy by antibody drug conjugate directed tumor radiosensitization to potentiate immunotherapies","volume":"9","author":"Mortaja","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"oyae344","DOI":"10.1093\/oncolo\/oyae344","article-title":"Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: A systematic review and meta-analysis","volume":"30","author":"Saldanha","year":"2025","journal-title":"Oncologist"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","article-title":"Overcoming resistance to antibody-drug conjugates: From mechanistic insights to cutting-edge strategies","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Wilski, N.A., Haytko, P., Zha, Z., Wu, S., Jin, Y., Chen, P., Han, C., and Chiu, M.L. (2025). A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17080967"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s40164-025-00685-w","article-title":"Advancing precision antibody-drug conjugate therapy: Unique proteogenomic profiles of tumor subsets in non-small cell lung cancer","volume":"14","author":"Lin","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_97","first-page":"217","article-title":"Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?","volume":"22","author":"Reuss","year":"2024","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_98","unstructured":"(2026, January 10). A Randomized, Phase 3, Open-Label Study to Evaluate Sigvotatug Vedotin Compared with Docetaxel in Adult Participants with Previously Treated Non-Small Cell Lung Cancer (Be6A Lung-01), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06012435."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/5\/677\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:33:15Z","timestamp":1777861995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/5\/677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":98,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["biom16050677"],"URL":"https:\/\/doi.org\/10.3390\/biom16050677","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]}}}